Kardigan
Kardigan is a clinical-stage biopharmaceutical company focused on targeted cardiovascular therapies. The company advances a portfolio of late-stage investigational programs (small molecules and antisense oligonucleotides) for genetic dilated cardiomyopathy, calcific aortic valve stenosis, and acute severe hypertension, and integrates a clinical intelligence platform to incorporate continuous real-world physiologic data and AI-driven analytics into drug development and trial execution.
Industries
Nr. of Employees
medium (51-250)
Products
Danicamtiv (investigational direct myosin activator)
Oral small-molecule cardiac myosin activator under clinical evaluation to restore atrial and ventricular myosin function in genetic dilated cardiomyopathy driven by sarcomeric variants.
Ataciguat (investigational sGC activator)
Once-daily oral soluble guanylate cyclase activator in development to target valvular calcification and remodeling in moderate calcific aortic valve stenosis.
Tonlamarsen (investigational angiotensinogen-targeted ASO)
Subcutaneous, once-monthly, liver-directed antisense oligonucleotide designed to reduce hepatic angiotensinogen production to modulate the renin-angiotensin-aldosterone system and lower blood pressure.
Danicamtiv (investigational direct myosin activator)
Oral small-molecule cardiac myosin activator under clinical evaluation to restore atrial and ventricular myosin function in genetic dilated cardiomyopathy driven by sarcomeric variants.
Ataciguat (investigational sGC activator)
Once-daily oral soluble guanylate cyclase activator in development to target valvular calcification and remodeling in moderate calcific aortic valve stenosis.
Tonlamarsen (investigational angiotensinogen-targeted ASO)
Subcutaneous, once-monthly, liver-directed antisense oligonucleotide designed to reduce hepatic angiotensinogen production to modulate the renin-angiotensin-aldosterone system and lower blood pressure.
Services
Clinical data platform integrating continuous physiologic monitoring, patient-facing data collection, and analytics to support trial design, patient monitoring, and endpoint assessment.
Structuring collaborations, licensing, and acquisitions to advance cardiovascular discovery, development, and commercialization.
Clinical data platform integrating continuous physiologic monitoring, patient-facing data collection, and analytics to support trial design, patient monitoring, and endpoint assessment.
Structuring collaborations, licensing, and acquisitions to advance cardiovascular discovery, development, and commercialization.
Expertise Areas
- Precision cardiology and biomarker-guided development
- Clinical trial design and execution (adaptive trials)
- Translational cardiovascular research
- Small-molecule and antisense oligonucleotide therapeutic development
Key Technologies
- Continuous remote physiologic monitoring (wearables, ECG, activity)
- Home-based high-density blood pressure monitoring
- AI-driven clinical analytics and predictive modeling
- Integration of FDA-regulated device algorithms (510(k) cleared)
News & Updates
Company launch with Series A financing to develop targeted cardiovascular medicines and an R&D model integrating data and translational tools.
Series B financing to advance three late-stage programs targeting specific cardiovascular disease drivers.
Conference presentations including late-breaking clinical and preclinical data and presentations from the clinical intelligence platform on continuous monitoring.
Phase 2 trial results showing reductions in plasma angiotensinogen and clinically meaningful within-group reductions in systolic blood pressure; supports further evaluation in acute severe hypertension.
Phase 2 data presented at the American Heart Association Scientific Sessions showing reduction in aortic valve calcium and improvements in ventricular structure and function.
Company launch with Series A financing to develop targeted cardiovascular medicines and an R&D model integrating data and translational tools.
Series B financing to advance three late-stage programs targeting specific cardiovascular disease drivers.
Conference presentations including late-breaking clinical and preclinical data and presentations from the clinical intelligence platform on continuous monitoring.
Phase 2 trial results showing reductions in plasma angiotensinogen and clinically meaningful within-group reductions in systolic blood pressure; supports further evaluation in acute severe hypertension.
Phase 2 data presented at the American Heart Association Scientific Sessions showing reduction in aortic valve calcium and improvements in ventricular structure and function.